Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Rock Springs Capital Management LP

Rock Springs Capital Management LP lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 27.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 487,863 shares of the company’s stock after acquiring an additional 104,371 shares during the quarter. Rock Springs Capital Management LP’s holdings in Vera Therapeutics were worth $20,632,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in VERA. Huntington National Bank bought a new stake in Vera Therapeutics during the fourth quarter valued at $26,000. AlphaQuest LLC acquired a new position in shares of Vera Therapeutics in the 4th quarter valued at about $34,000. KBC Group NV grew its position in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after buying an additional 1,387 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after acquiring an additional 639 shares during the period. Finally, Moors & Cabot Inc. bought a new position in Vera Therapeutics in the fourth quarter worth about $220,000. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA opened at $21.29 on Monday. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -8.16 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The stock’s 50 day moving average price is $26.09 and its 200 day moving average price is $36.47.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VERA. Guggenheim increased their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JPMorgan Chase & Co. cut their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target for the company. Finally, Wolfe Research initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $64.67.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.